All Times EDT
The presentation will cover concepts to address new safety challenges like cytokine-release syndrome (CRS) and dose finding strategies. We will discuss potential approaches to support dose-finding in cancer immunotherapies e.g. when split-dose approaches are utilized. Second, we will discuss design optimization for the selection of the recommended phase II dose via expansion or backfill cohorts based on potential biomarkers coming from different data sources.